United Therapeutics Corporation (UTHR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $25.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
United Therapeutics Corporation (UTHR) Earnings: Report Dates and Results
United Therapeutics (UTHR) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, United Therapeutics reported EPS of $5.71, below the $5.85 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
UTHR has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.5% below the $7.70 reported for the quarter ended Dec 31, 2025.
UTHR Earnings Call
The latest UTHR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, UTHR beat 19, missed 19 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $832.50M, up 4.1% from $799.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $5.71 | $5.85 | $4.40 - $7.26 | -2.39% | Miss | -20.3% | 14 | 2 up, 3 down | Nov 4, 2026 | $832.50M |
| Jun 30, 2026 | $7.27 | $6.82 | $6.07 - $7.76 | +6.60% | Beat | +13.4% | 12 | 1 up, 1 down | Aug 5, 2026 | $783.30M |
| Mar 31, 2026 | $5.82 | $6.86 | $6.36 - $7.41 | -15.16% | Miss | -12.2% | 12 | 1 up, 3 down | May 6, 2026 | $781.50M |
| Dec 31, 2025 | $7.70 | $7.10 | $3.01 - $7.94 | +8.45% | Beat | +24.4% | 12 | 0 up, 0 down | Feb 25, 2026 | $790.20M |
| Sep 30, 2025 | $7.16 | $6.96 | $6.08 - $7.67 | +2.87% | Beat | +1.3% | 12 | 1 up, 1 down | Oct 29, 2025 | $799.50M |
| Jun 30, 2025 | $6.41 | $7.30 | $5.92 - $7.43 | -12.19% | Miss | +9.6% | 11 | 1 up, 2 down | Jul 30, 2025 | $798.60M |
| Mar 31, 2025 | $6.63 | $6.54 | $5.35 - $7.07 | +1.38% | Beat | +7.5% | 10 | N/A | Apr 30, 2025 | $794.40M |
| Dec 31, 2024 | $6.19 | $6.27 | $5.03 - $7.04 | -1.23% | Miss | +42.0% | 12 | 1 up, 1 down | Feb 26, 2025 | $735.90M |
| Sep 30, 2024 | $7.07 | $7.12 | $5.41 - $7.41 | -0.70% | Miss | +31.4% | 13 | 2 up, 0 down | Oct 30, 2024 | $748.90M |
| Jun 30, 2024 | $5.85 | $6.41 | $5.59 - $7.47 | -8.74% | Miss | +11.6% | 12 | 5 up, 1 down | Jul 31, 2024 | $714.90M |
| Mar 31, 2024 | $6.17 | $5.59 | $4.75 - $6.53 | +10.38% | Beat | +27.0% | 13 | 1 up, 0 down | May 1, 2024 | $677.70M |
| Dec 31, 2023 | $4.36 | $4.19 | $2.97 - $5.40 | +4.06% | Beat | +63.3% | 14 | 1 up, 1 down | Feb 21, 2024 | $614.70M |
| Sep 30, 2023 | $5.38 | $5.04 | $4.01 - $5.67 | +6.75% | Beat | +9.6% | 11 | 1 up, 0 down | Nov 1, 2023 | $609.40M |
| Jun 30, 2023 | $5.24 | $4.78 | N/A | +9.62% | Beat | +51.4% | 11 | 2 up, 0 down | Aug 2, 2023 | $596.50M |
| Mar 31, 2023 | $4.86 | $4.71 | $3.96 - $4.99 | +3.18% | Beat | -3.4% | 12 | 1 up, 0 down | May 3, 2023 | $506.90M |
| Dec 31, 2022 | $2.67 | $4.51 | $3.34 - $5.23 | -40.80% | Miss | +13.6% | 11 | 1 up, 0 down | Feb 22, 2023 | $491.50M |
| Sep 30, 2022 | $4.91 | $3.77 | $2.90 - $4.86 | +30.24% | Beat | +43.6% | 11 | 1 up, 1 down | Nov 2, 2022 | $516.00M |
| Jun 30, 2022 | $3.46 | $4.54 | $3.42 - $4.63 | -23.79% | Miss | -15.4% | 9 | 0 up, 2 down | Aug 3, 2022 | $466.90M |
| Mar 31, 2022 | $5.03 | $3.07 | $2.27 - $3.99 | +63.84% | Beat | +44.1% | 9 | 1 up, 0 down | May 4, 2022 | $461.90M |
| Dec 31, 2021 | $2.35 | $3.72 | $3.40 - $4.07 | -36.83% | Miss | +7.3% | 8 | N/A | Feb 24, 2022 | $415.20M |
| Sep 30, 2021 | $3.42 | $3.58 | $3.12 - $4.26 | -4.47% | Miss | -11.9% | 7 | N/A | Nov 3, 2021 | $444.70M |
| Jun 30, 2021 | $4.09 | $3.56 | N/A | +14.89% | Beat | +11.1% | 7 | N/A | Aug 4, 2021 | $446.50M |
| Mar 31, 2021 | $3.49 | $3.49 | $2.37 - $3.61 | 0.00% | In line | -3.3% | 8 | N/A | May 5, 2021 | $379.10M |
| Dec 31, 2020 | $2.19 | $3.14 | $2.70 - $3.76 | -30.25% | Miss | +82.5% | 8 | N/A | Feb 24, 2021 | $1.13B |
| Sep 30, 2020 | $3.88 | $3.34 | $1.92 - $3.49 | +16.17% | Beat | +1.3% | 8 | N/A | Oct 28, 2020 | N/A |
| Jun 30, 2020 | $3.68 | $3.28 | $2.16 - $3.53 | +12.20% | Beat | +1.4% | 7 | N/A | Jul 29, 2020 | N/A |
| Mar 31, 2020 | $3.61 | $3.39 | N/A | +6.49% | Beat | N/A | 8 | N/A | Apr 29, 2020 | $356.30M |
| Dec 31, 2019 | $1.20 | $2.68 | $1.53 - $3.35 | -55.22% | Miss | -18.9% | 6 | N/A | Feb 26, 2020 | $311.10M |
| Sep 30, 2019 | $3.83 | $2.90 | $1.88 - $3.23 | +32.07% | Beat | +58.3% | 7 | N/A | Oct 30, 2019 | $401.50M |
| Jun 30, 2019 | $3.63 | $2.74 | $1.90 - $3.07 | +32.48% | Beat | -16.7% | 8 | N/A | Jul 31, 2019 | $373.60M |
| Mar 31, 2019 | -$11.32 | $2.77 | $2.13 - $3.73 | -508.66% | Miss | -401.1% | 9 | N/A | May 1, 2019 | $362.60M |
| Dec 31, 2018 | $1.48 | $2.55 | $1.82 - $3.07 | -41.96% | Miss | -62.0% | 8 | N/A | Feb 27, 2019 | $381.40M |
| Sep 30, 2018 | $2.42 | $3.03 | $2.45 - $3.87 | -20.13% | Miss | -48.4% | 7 | N/A | Oct 31, 2018 | $412.70M |
| Jun 30, 2018 | $4.36 | $3.42 | $2.55 - $3.94 | +27.49% | Beat | -0.2% | 7 | N/A | Aug 1, 2018 | $444.50M |
| Mar 31, 2018 | $3.76 | $4.00 | $2.65 - $4.46 | -6.00% | Miss | +4.2% | 8 | N/A | May 2, 2018 | $389.20M |
| Dec 31, 2017 | $3.89 | $3.89 | $2.84 - $4.87 | 0.00% | In line | +56.2% | 9 | N/A | Feb 21, 2018 | $464.70M |
| Sep 30, 2017 | $4.69 | $4.80 | N/A | -2.29% | Miss | +7.6% | 10 | N/A | Oct 25, 2017 | $445.50M |
| Jun 30, 2017 | $4.37 | $3.66 | $2.85 - $4.09 | +19.40% | Beat | -0.5% | 9 | N/A | Jul 27, 2017 | $444.60M |
| Mar 31, 2017 | $3.61 | $3.82 | N/A | -5.50% | Miss | +19.5% | N/A | N/A | Apr 26, 2017 | $370.50M |
| Dec 31, 2016 | $2.49 | $3.61 | N/A | -31.02% | Miss | +18.6% | N/A | N/A | Feb 22, 2017 | $409.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $27.90, up 10.4% from the year before. It was $14.26 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $27.90 | +10.4% |
| Dec 31, 2024 | $25.28 | +27.4% |
| Dec 31, 2023 | $19.84 | +23.5% |
| Dec 31, 2022 | $16.07 | +20.4% |
| Dec 31, 2021 | $13.35 | N/A |
| Dec 31, 2020 | $13.36 | N/A |
| Dec 31, 2019 | -$2.66 | -122.1% |
| Dec 31, 2018 | $12.02 | -27.4% |
| Dec 31, 2017 | $16.56 | +16.1% |
| Dec 31, 2016 | $14.26 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,200 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,179 | 15 | |
| 2026Q2 | Jun 30, 2026 | 4,136 | 14 | |
| 2026Q1 | Mar 31, 2026 | 4,217 | 13 | |
| 2025Q4 | Dec 31, 2025 | 3,733 | 9 | |
| 2025Q3 | Sep 30, 2025 | 3,539 | 12 | |
| 2025Q2 | Jun 30, 2025 | 6,396 | 16 | |
| 2025Q1 | Mar 31, 2025 | 4,068 | 12 | |
| 2024Q4 | Dec 31, 2024 | 4,274 | 11 |
2026Q3 Earnings Call
Opening remarks
Harry Silvers Investor Relations Thank you, Krista. Good morning, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation Third Quarter 2026 Corporate Update webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the products is available on our website. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer, Michael Benkowitz, our President and Chief Operating Officer, James Edgemond, our Chief Financial Officer and Treasurer, Dr. Leigh Peterson, our Executive Vice President of Product Development and Xenotransplantation, and Pat Poisson, our Executive Vice President of Strategic Development. Note that James Edgemond and I will participate in a fireside chat and one-on-one sessions at the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference in London on November 16th and 17th, respectively. Additionally, members from our management team will participate in a fireside chat and one-on-one meetings at the 45th Annual J.P. Morgan Healthcare Conference in San Francisco in January of next year. Our scientific, commercial, and medical affairs teams will be present at PHenomenal Hope 2026 on December 4th in Boston and at the Pulmonary Vascular Research Institute Annual Congress in Bangkok in late January of next year. I will turn the webcast over to Martine for an overview of our development pipeline and business activities. Martine.
Martine Rothblatt Chairperson and CEO Thank you, Harry, and good morning, everyone. We have slides available for reference, and I encourage you to review those at your leisure. I am not going to speak directly to the slides. As we look back on the third quarter, I am incredibly proud of what our teams have accomplished. We executed at a high level across our business and across our company, delivering for patients while advancing one of the most ambitious growth strategies in biotechnology. The significance of this quarter extends beyond any individual result or milestone. It reflects the broader transformation underway at United Therapeutics as we build a comprehensive cardiopulmonary and respiratory medicine franchise capable of reaching dramatically more patients than ever before. For most of our history, UT has been known as a pulmonary hypertension company.
Frequently Asked Questions About UTHR
When is United Therapeutics's next earnings date?
United Therapeutics's next earnings report is expected for Feb 23, 2027.
Did UTHR beat earnings estimates last quarter?
No. United Therapeutics reported EPS of $5.71 for the quarter ended Sep 30, 2026, below the $5.85 estimate by 2.39%.
What EPS do analysts expect from UTHR next quarter?
The consensus EPS estimate for United Therapeutics for the quarter ending Dec 31, 2026 is $6.89 from 16 analysts, with estimates from $2.99 to $13.46.
How often does UTHR beat earnings estimates?
United Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.46%.
UTHR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts